Insights from studies of blood substitutes in trauma.
Most authorities believe that the greatest need for blood substitutes is in patients with unanticipated acute blood loss, and trauma is the most likely scenario. The blood substitutes reaching advanced clinical trials today are red blood cell (RBC) substitutes, derived from hemoglobin. The hemoglobin-based oxygen carriers (HBOCs) tested currently in FDA Phase III clinical trials are polymerized hemoglobin solutions. The standard approach to restoring oxygen delivery in hemorrhagic shock has been crystalloid administration to expand intravascular volume, followed by stored RBCs for critical anemia. However, allogenic RBCs may have adverse immunoinflammatory effects that increase the risk of postinjury multiple organ failure (MOF). Phase II clinical trials, as well as in vitro and in vivo work, suggest that resuscitation with a HBOC--in lieu of stored RBCs--attenuates the systemic inflammatory response invoked in the pathogenesis of MOF. Specifically, an HBOC has been shown to obviate stored RBC provoked neutrophil priming, endothelial activation, and systemic release of interleukins 6, 8, and 10. Based on this background and work by others, we have initiated a multicenter prehospital trial in which severely injured patients with major blood loss (systemic blood pressure <90 mmHg) are randomized to initial field resuscitation with crystalloid versus HBOC. During the hospital phase, the control group is further resuscitated with stored RBCs, whereas the study group receives HBOC (up to 6 units) in the first 12 h. The primary study endpoint is 30-day mortality, and secondary endpoints include reduction in allogenic RBCs, hemoglobin levels <5 g/dL, uncrossmatched RBCs, and MOF. The potential efficacy of HBOCs extends beyond the temporary replacement for stored RBCs. Hemoglobin solutions might ultimately prove superior in delivering oxygen to ischemic or injured tissue. The current generation of HBOCs can be lifesaving for acute blood loss today, but the next generation might be biochemically tailored for specific clinical indications.
Moore
Ernest E
EE
Department of Surgery, Denver Health Medical Center and University of Colorado Health Sciences Center, Denver, Colorado 80204, USA. Ernest.moore@dhha.org
Johnson
Jeffrey L
JL
Cheng
Aaron M
AM
Masuno
Tomohiko
T
Banerjee
Anirban
A
D001802:Blood Substitutes / Q000737:chemistry* / Q000627:therapeutic use*; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D004912:Erythrocytes / Q000166:cytology / Q000378:metabolism; D006454:Hemoglobins / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D007249:Inflammation; D016753:Interleukin-10 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism; D015337:Multicenter Studies as Topic; D009504:Neutrophils / Q000166:cytology; D009569:Nitric Oxide / Q000737:chemistry; D010100:Oxygen / Q000378:metabolism; D011108:Polymers / Q000737:chemistry; D012771:Shock, Hemorrhagic / Q000628:therapy*; D014947:Wounds and Injuries / Q000628:therapy*
D001802:Blood Substitutes; D006454:Hemoglobins; D015850:Interleukin-6; D016209:Interleukin-8; D011108:Polymers; D016753:Interleukin-10; D009569:Nitric Oxide; D010100:Oxygen